Senti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting different combinations of immune mediators. It has landed on MSCs that home to ovarian tumors and produce IL-12 and IL-21, the best performing cytokine combination to emerge from its systematic in vivo screens.

Senti Biosciences Inc. will present preclinical data for SENTI-101 on Saturday at the 2019 meeting of the Society for Immunotherapy of Cancer (SITC). ...